In 2018, 36 of the 65 newly approved medications in Germany were biopharmaceuticals – an unprecedented fifty-eight percent.
“An unbelievable record” says Frank Matthias, chairman of the Association of Research Pharmaceutical Producers (VFA).
Sales of biopharmaceuticals increased by 11.7 percent over 2017, reaching 11.4 billion euros. 400 medical biotechnology companies operate in Germany, of which 119 are already marketing biopharmaceuticals and/or have their own product pipelines. The remaining 281 contribute to drug development in other ways.
One of the focuses of biopharmaceutical research is on autoimmune diseases that are caused by an overreaction of the immune system to the body’s own cells or tissues and that affect at least five percent of the world population.